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Fig. 1. (A) Radiotherapy plan and (B) dermatitis observed in 
irradiated skin. 
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Dear Editor:
A 53-year-old man with recurrent penile carcinoma 
presented to his physician with an erythematous rash and 
pruritus. The patient had undergone a partial penectomy 
for the treatment of penile squamous cell carcinoma in 
2002. Seven years later, he presented with penile stump 
and inguinal masses, and underwent a total penectomy 
and right superficial inguinal lymph node dissection. The 
histologic examination of the enlarged lymph node showed 
evidence of metastasis. At that time, a bilateral inguinal 
and pelvic lymphadenectomy was considered, but the 
patient refused it because of the significant risk of morbi-
dity. As an alternative treatment, he received radiotherapy 
of 7,020 cGy. Four months later, he was referred for 
palliative chemotherapy due to disease progression. The 
patient was to be treated with paclitaxel 175 mg/m
2 and 
cisplatin 70 mg/m
2 every three weeks. Five days after the 
initiation of chemotherapy, he developed an erythematous 
rash with pruritus in the lower abdomen and pelvis which 
was compatible with the previous radiation field (Fig. 1). 
The diagnosis of radiation recall dermatitis was made 
based on the clinical history and appearance of the tissue. 
This observed skin change resolved completely with oral 
prednisolone and antihistamine over a course of six days. 
After a discussion with the patient, the paclitaxel and 
cisplatin were continued with close observation of his skin 
reaction. The skin alterations reappeared to a milder 
degree than that observed with the initial occurrence. The 
patient completed six scheduled cycles of palliative 
chemotherapy with a partial response.
Radiation recall dermatitis refers to the reappearance of 
radiotherapy-like reactions in previously irradiated skin 
after the administration of drugs, especially chemo-SW Baek, et al
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therapeutic agents or antibiotics
1,2. It was first described 
by D’Angio et al.
3 in 1959 with actinomycin D treatment. 
Subsequently, anticancer drugs have been associated with 
this phenomenon, including 5-fluorouracil, hydroxyurea, 
vinblastine, methotrexate, adriamycin, etoposide, tamoxifen, 
bleomycin, paclitaxel, docetaxel, gemcitabine, pemetrexed, 
trastuzumab, and erlotinib
4-8. In our case, both paclitaxel 
and cisplatin could precipitate a radiation recall reaction 
because each drug was reported to be associated with the 
development of radiation recall dermatitis
9. Although 
numerous organs can be affected, this phenomenon is rare 
and most reports describe the appearance of skin lesions. 
The time interval between the end of radiotherapy and the 
administration of the drug responsible for the cutaneous 
reaction can range from two days to 15 years, although 
the most frequent interval is several weeks or months, as 
reported in our case study. The typical skin lesion consists 
of a maculopapular rash, edema, erythema, vesicles, or 
desquamation. Pruritus is usually present, while pain and 
skin necrosis are possible in severe cases
1,4,8. The patho-
physiology of this phenomenon remains poorly under-
stood, although several hypotheses involving epithelial 
stem cell deficiency, vascular damage, drug hypersensitivity, 
or epithelial stem cell sensitivity have been proposed
4,8. 
Discontinuation of the responsible drug usually results in 
the resolution of radiation dermatitis. Steroids and antihis-
tamines control the pruritus and pain. Repeat challenge 
with the offending drug may provoke another recall 
reaction, but this is not usually the case. Usually, the 
recurrence of radiation recall dermatitis presents with 
milder clinical signs than the original episode. However, 
the main question is still whether chemotherapy should be 
continued after the first manifestation of radiation recall 
dermatitis, especially if there is a limited choice of avail-
able drugs. The decision should consider the benefits and 
potential risks of re-challenge with the same drug
10. 
Considering the increased use of combination radio-
therapy and chemotherapy in the treatment of malignant 
disease, clinicians need improved knowledge of radiation 
recall dermatitis and its management.
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